We improve patient outcomes by empowering healthcare professionals to make better informed clinical decisions, leading to more efficient patient triage
Triage suPARcharged
The suPAR biomarker predicts critical illness across diseases, by measuring the level of activation in the immune response. suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at emergency departments in hospitals.
How to interpret suPAR results
suPAR level < 4 ng/ml
Supports patient discharge
suPAR level > 6 ng/ml
Supports patient hospitalisation
Lead with confidence
suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better informed decisions, backed by reliable biological data across diseases.
Implementing the biomarker suPAR in clinical care delivers faster and safer patient discharges, reduces re-admissions, unnecessary admissions as well as hospital length of stay. – Freeing up critical resources, valuable time and saving hospital beds for those who need them.
Improve patient care
Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient
Reduce healthcare costs
Up to €100-380 savings per admission depending on medical specialty and geography
Empower clinical staff
Get more information to make more confident decisions to potentially reduce uncertainty and stress
COVID-19 triaging using the inflammatory biomarker suPAR
The prognostic biomarker suPAR is currently used across various hospitals in Europe to manage COVID-19 patients.
The admission suPAR level is an early indicator for the risk of developing severe respiratory failure and requiring mechanical ventilation*.
Using admission suPAR levels for COVID-19 patients, physicians may identify low-risk patients for early discharge to reduce the pressure on COVID-19 hospitals, i.e., at emergency departments and in intensive care units <sup>4,5</sup>. Furthermore, physicians may identify high-risk patients for early treatment.
COVID-19 hospitals using suPAR for risk stratification may experience:
- Improved patient care with fewer unnecessary admissions, fewer re-admissions, early treatment intervention, and shorter length-of-stay
- Empowered clinical staff with more information to make confident decisions reducing stress and uncertainty
- Reduced healthcare costs
suPAR is a naturally occurring protein measurable in all humans reflecting immune activation. The protein is associated with inflammation and adverse outcomes across life threatening diseases. suPAR can be measured in clinical routine using the suPARnostic® TurbiLatex product that fits existing hospital work flows and instruments. suPARnostic® TurbiLatex is validated for use on clinical chemistry analysers from Roche Diagnostics, Siemens Healthineers, and Abbott.
“suPAR can be a strong tool for the much-needed early risk stratification of patients with COVID-19.”
Prof. Ove Andersen, MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark. suPAR News Vol. 3, June 2020
“ViroGates aims to make a difference by empowering healthcare professionals in their clinical decision making, ultimately leading to improved patient care and reduced healthcare costs. We are committed to providing hospitals with high-quality prognostic biomarker products. I am proud of the accomplishments of our employees in spreading the suPAR message and look forward to continuing to make a positive impact on healthcare globally”
– Jakob Knudsen, CEO at ViroGates
“It has become clear that suPAR is a very strong prognostic marker, exceeding the prognostic value of all other routinely measured biomarkers in our hospital.”
Prof. Ove Andersen,
MD, PhD, DmSc, Copenhagen University Hospital Hvidovre, Denmark
suPAR News Vol. 3, June 2020
How suPARnostic® works at the Emergency Department
Step 1
A patient is admitted to the ED for observation
Step 2
The patient’s blood sample is drawn
Step 3
The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.
Step 4
The physician gets the result and makes a triage decision
COVID-19 patient outcome
COVID-19 patient outcome
Need for mechanical ventilation
(exploratory study)
| n = 57 | Need for mechanical ventilation | No need for mechanical ventilation | PPV/NPV |
|---|---|---|---|
| suPAR > 6 ng/ml | 18 | 3 | PPV 85.7% |
| suPAR ≥ 4 and ≤ 6 ng/ml | 3 | 20 | PPV 13.0% |
| suPAR < 4 ng/ml | 0 | 13 | NPV 100.0% |
| Sensitivity/ Specificity (suPAR < 4 ng/ml) | Sensitivity 100.0% | Specificity 36.1% |
Source: Rovina, N. et al. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care24, 187 (2020).
suPAR is a significant independent predictor of mortality of ED patients
| n = 4,343 | Patients dead after 30 days | Patients alive after 30 days | PPV/NPV |
|---|---|---|---|
| suPAR ≥6 ng/ml | 133 | 509 | PPV 20.7% |
| suPAR >3 and l | 77 | 1,580 | |
| suPAR ≤3 ng/ml | 14 | 2,030 | NPV 99.3% |
| Sensitivity/Specificity (suPAR ≤3 versus ≥6 ng/ml) | Sensitivity 90.5% | Specificity 80.0% |
Source: Rasmussen LJH, Ladelund S, Haupt TH, et al. Emerg Med J 2016;33:769-775
* suPAR values should be used in conjunction with clinical findings and the results of other laboratory parameters. suPAR values alone are not indicative of the need for mechanical ventilation.
1. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Rovina N et al. Crit Care. 2020 4(1):187. (LINK: https://pubmed.ncbi.nlm.nih.gov/32354367/
2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU et al. J Am Soc Nephrol. 2020 (LINK: https://pubmed.ncbi.nlm.nih.gov/32963090/
3. Soluble Urokinase-Guided Anakinra To Prevent Respiratory Failure In COVID-19: A Single-Arm Trial. Kyriazopoulou E et al. (preprint, link to be provided when available)
4. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Chalkias A et al. Mol Diagn Ther. 2020 (5):517-521. (LINK: https://pubmed.ncbi.nlm.nih.gov/32613288/
5. COVID-19 and pneumonia: a role for the uPA/uPAR system. D’Alonzo D et al. Drug Discov Today. 2020 (8):1528-1534. Review. (LINK: https://pubmed.ncbi.nlm.nih.gov/32562843/
